AOD 9604 (5 MG)

Description

AOD 9604 is an altered version of the hGH fragment 176-191 peptide (contains a di-sulfide bridge) and hence a derivative of human growth hormone (hGH). Originally found as a lipolytic (fat burning) compound, AOD 9604 has shown proven benefits in studies of heart disease, osteoarthritis/cartilage repair, and metabolic syndrome. AOD9604 expedites lipolysis (the breakdown or destruction of fat) and inhibits lipogenesis in animal studies.

AOD 9604 and Obesity Research

AOD9604 was originally researched as an analogue of HGH with the sole purpose of curing obesity. Phase 2b clinical trials were completed in Australia testing the drug in 300 obese humans. The results of the continuous administration for 12 weeks (once in a day) showed that the drug tripled the pace of weight loss journey when compared to placebo and that the rate of weight loss also remained steady during the trial period[3], [4]. This fact indicates that a resistance to the peptide is unlikely to arise and that longer and regular treatment would result in even greater weight loss.

Research in mice that are genetically vulnerable to obesity indicates that AOD 9604 likely does not work only by stirring the beta-3- adrenergic receptors found on white fat. It was originally contemplated that the peptide is bound to these receptors and increased the rate of metabolism in fat cells resulting in the shift from a storage mode to a usage mode. It turns out that even in mice lacking these receptors, faster fat loss takes place when AOD 9604 is administered[5]. Though the beta-3- adrenergic receptor likely plays a role in fat loss secondary to AOD 9604, at least one other mechanism must be in play as well. There is some thought that AOD 9604 may indirectly activate apoptosis in white fat cells.

Joint Pain and Function

Research in rats indicates that injections of AOD9604 directly into arthritic joints can do wonders. As it works in synergy with existing therapies to treat pain, mitigates disability, and improve quality of life[6]. Changes in both gross clinical exam and microscopic structure of cartilage in the affected joints indicates that AOD9604 is effective in treating the root cause of osteoarthritis and may work as both a treatment and preventative measure. Even though AOD9604 is effective in mitigating joint dysfunction on its own, it works better in combination with other therapies. It isn’t clear how the synergy arises, but more research using the peptide may reveal novel pathways for improving cartilage growth, a notoriously challenging clinical problem.

AOD9604 and Heart Disease

Though fat reduction and weight loss directly decreases the risk of heart disease, there is evidence to suggest that AOD 9604 has beneficial effects on the heart beyond its ability to reduce fat burden. It is thought that the peptide may directly affect metabolism in such a way to reduce complications separate from its effects on obesity. This is not unheard of, as drugs like pioglitazone and acipimox both reduce metabolic complications without treating obesity at all. It is thought that the secondary pathway by which AOD 9604 causes fat loss may play a role in improving metabolic metrics even while it boosts fat loss[7].

Article Author

The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Scientific Journal Author

Stier Heike studied biology and holds a PhD in Neurobiology (NMIReutlingen/ University of Hohenheim) and a Master in Bioinformatics (University of Applied Sciences-TFH-Berlin). She worked as a Post-Doc in several national and international Labs in Developmental Neurobiology (NMI-Reutlingen, School of Medicine – University of Utah) and in Bioinformatics (Institute of Bioinformatics –Charité, Berlin). Dr. Heike pioneered a study on the safety and tolerability of the Hexadecapeptide AOD9604 in Humans. In 2007, she joined A&R where she was responsible for the field of regulatory affairs of herbal medicinal products, with a broad knowledge of the adjacent product categories medical device and supplements. Dr. Heike Stier currently works in the field of regulatory affairs for herbal medicinal products at analyze & realize GmbH.

Stier Heike is being referenced as one of the leading scientists involved in the research and development of AOD9604. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between PeptidesforSale.com and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Dr. Heike is listed in [8] under the referenced citations.

Referenced Citations

[1] F. M. Ng, J. Sun, L. Sharma, R. Libinaka, W. J. Jiang, and R. Gianello, “Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone,” Horm. Res., vol. 53, no. 6, pp. 274–278, 2000. [PubMed]

[2] H. Stier, E. Vos, and D. Kenley, “Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans,” J. Endocrinol. Metab., vol. 3, no. 1–2, pp. 7-15–15, Apr. 2013. [Journal of Endocrinology & Metabolism]

[3] “Obesity drug codenamed AOD9604 highly successful in trials,” News-Medical.net, 16-Dec-2004. [Online]. Available: https://www.newsmedical.net/news/2004/12/16/6878.aspx. [Accessed: 24-May-2019].

[4] R. Zieba, “[Obesity: a review of currently used antiobesity drugs and new compounds in clinical development],” Postepy Hig. Med. Doswiadczalnej Online, vol. 61, pp. 612–626, Oct. 2007. [PubMed]

[5] M. Heffernan et al., “The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice and β 3- AR Knock-Out Mice,” Endocrinology, vol. 142, no. 12, pp. 5182–5189, Dec. 2001. [PubMed]

[6] D. R. Kwon and G. Y. Park, “Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model,” Ann. Clin. Lab. Sci., vol. 45, 4, pp. 426–432, Jul. 2015. [PubMed]

[7] M. D. Jensen, “Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors,” Obes. Silver Spring Md, vol. 14 Suppl 3, pp. 143S-149S, Jun. 2006. [Wiley Online Library]

[8] STIER, H., VOS, E., KENLEY, D.. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism, North America, 3, apr. 2013. Available at:<https://www.jofem.org/index.php/jofem/article/view/157>